Phase 2
Completed N=88
Anastrozole Administration in Elderly Hypogonadal Men
Source: ClinicalTrials.gov NCT00136695 ↗Enrolled (actual)
88
Serious AEs
7.2%
Results posted
Jan 2017
Primary outcomePrimary: Change in Lean Body Mass — -2000; -1500 grams
Summary
The purpose of the study is to assess the effects of sustained aromatase inhibitor therapy to reduce estrogen levels in elderly men with mild hypogonadism (a decreased level of sex hormones).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Lean Body Mass |
-2000; -1500 | — |
Eligibility Criteria
Inclusion Criteria
- Men ages 60 and older
- Serum testosterone between 150-300 ng/dL
- Symptoms suggestive of androgen deficiency
Data sourced from ClinicalTrials.gov (NCT00136695). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.